Chat with us, powered by LiveChat

Wana Brands Products Now Available to Illinois Medical Marijuana Patients

CHICAGO (February 6, 2019)—Medical cannabis patients across Illinois now have access to Wana Brands products, the nation’s most dependable infused edibles, just as the state kicks off the new Opioid Alternative Pilot Program allowing patients suffering from conditions that require an opioid prescription to purchase cannabis. Wana Brands’ consistent, top-quality medical cannabis products are available in Illinois dispensaries through an exclusive licensing agreement with Grassroots Cannabis, Illinois’ largest medical cannabis company.

Wana flavors and ratios available in Illinois include Blueberry Indica (100 mg per package, 10 pieces) and Mango Sativa (100 mg per package, 10 pieces). Known for consistent dosing, Wana gummies are handcrafted and infused with high-quality tincture during the cooking process to ensure the best tasting, highest quality, consistent gummie on the market. Wana gummies are made with fruit pectin, not gelatin. A specially selected fruit pectin gives Wana Sour Gummies their amazing texture and makes them vegan. All Wana products are made with gluten-free ingredients and taste like real fruit, thanks to all-natural flavoring, coloring and sugar. Wana Gummies also have no sorbitol or mineral oil, both of which can cause stomach upset.

“Cannabis offers a safe alternative to the deadly opioid crisis,” said Nancy Whiteman, CEO of Wana Brands. “Wana Brands is ready to provide safe and consistent products to the state’s medical marijuana patients.”

More than 52,000 patients have joined Illinois’ Medical Cannabis Registry Program since it launched in September 2014, with those numbers expected to double as the Opioid Alternative Pilot Program comes online. Now doctors are allowed to prescribe medical marijuana instead of opioids to help patients with chronic pain, stemming from cancer or other medical issues. Qualifying medical conditions include HIV / AIDS, ALS, Alzheimer’s disease, cancer, Crohn’s disease, severe fibromyalgia, glaucoma, hepatitis C, lupus, multiple sclerosis, muscular dystrophy, Parkinson’s disease, epilepsy, spinal cord disease / injury, traumatic brain injury and post-traumatic stress disorder (PTSD).

With availability to medical patients in Illinois, Wana Brands’ continues expansion from its Colorado headquarters. The Company’s consistent and potent medical marijuana products are also available in Colorado, Arizona, Nevada and Oregon dispensaries, with Florida, Michigan and Ohio among the states imminently coming online. Wana Brands expects to expand into California, Maryland, Pennsylvania and internationally in Canada through 2020. Wana Brands is the No. 1 infused cannabis brand in the United States, selling more units and dollars than any other cannabis products company, according to BDS Analytics.

For more information or to schedule an interview, please contact

Wana Brands: Enhance Your Life.

Included in the 2018 Inc. 5000 list at #1087 and boasting a three-year growth rate of 455%, Wana Brands is the No. 1 edibles brand in the United States, with more units and dollars sold than any other brand, according to BDS Analytics. Wana leads the industry in quality, consistency and potency, featuring a carefully curated line of edibles, including market-leading gummies and WanaCapsXR, a family of extended-release cannabis capsules that provide symptom relief for up to 12 hours. Wana products are available in Colorado, Arizona, Oregon, Nevada and Illinois. Wana is currently onboarding in Florida and Michigan to serve medical marijuana patients in those markets by end of 2019. The Company expects to enter California, Maryland, Ohio, Pennsylvania, Oklahoma, Missouri, Massachusetts, New Jersey and internationally in Canada by 2020. For more information or to subscribe to Wana’s e-newsletter, visit Follow Wana on Facebook, Instagram, LinkedIn and Twitter.


Buy Now